TRANSLOCATION
MOLECULAR BASIS OF ANTIBIOTIC TRANSLOCATION
| Coordinatore | JACOBS UNIVERSITY BREMEN GGMBH
Organization address
address: Campus Ring 1 contact info |
| Nazionalità Coordinatore | Germany [DE] |
| Totale costo | 3˙304˙341 € |
| EC contributo | 3˙304˙341 € |
| Programma | FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) |
| Code Call | FP7-PEOPLE-2013-ITN |
| Funding Scheme | MC-ITN |
| Anno di inizio | 2013 |
| Periodo (anno-mese-giorno) | 2013-09-01 - 2017-08-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
JACOBS UNIVERSITY BREMEN GGMBH
Organization address
address: Campus Ring 1 contact info |
DE (BREMEN) | coordinator | 625˙640.18 |
| 2 |
UNIVERSITA DEGLI STUDI DI CAGLIARI
Organization address
address: VIA UNIVERSITA 40 contact info |
IT (CAGLIARI) | participant | 663˙400.72 |
| 3 |
THE UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS
Organization address
address: NORTH STREET 66 COLLEGE GATE contact info |
UK (ST ANDREWS FIFE) | participant | 285˙056.64 |
| 4 |
UNIVERSITY OF NEWCASTLE UPON TYNE
Organization address
address: Kensington Terrace 6 contact info |
UK (NEWCASTLE UPON TYNE) | participant | 285˙056.64 |
| 5 |
BioVersys AG
Organization address
address: Hochbergerstrasse 60c contact info |
CH (Basel) | participant | 261˙515.76 |
| 6 |
UNIVERSITAET BASEL
Organization address
address: Petersplatz 1 contact info |
CH (BASEL) | participant | 261˙515.76 |
| 7 |
UNIVERSITE D'AIX MARSEILLE
Organization address
address: Boulevard Charles Livon 58 contact info |
FR (Marseille) | participant | 255˙948.66 |
| 8 |
FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V
Organization address
address: Hansastrasse 27C contact info |
DE (MUENCHEN) | participant | 222˙068.88 |
| 9 |
JOHANN WOLFGANG GOETHE UNIVERSITAET FRANKFURT AM MAIN
Organization address
address: GRUNEBURGPLATZ 1 contact info |
DE (FRANKFURT AM MAIN) | participant | 222˙068.88 |
| 10 |
Nanion Technologies GmbH
Organization address
address: GABRIELENSTRASSE 9 contact info |
DE (MUNCHEN) | participant | 222˙068.88 |
| 11 |
EUROPEAN SCREENINGPORT GMBH
Organization address
address: SCHNACKENBURGALLEE 114 contact info |
DE (HAMBURG) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Multidrug resistant bacteria are now ubiquitous in both hospitals and the larger community. Drug-resistant pathogens are becoming increasingly pervasive, for example, the resurrection of tuberculosis provides one ominous example highlighting the risk associated with evolved drug resistance. Moreover, many pharmaceutical companies abandoned this field and no truly novel active antibacterial compounds are currently in clinical trials. Obviously we need new antibacterial molecules and maybe, novel strategies to develop antibiotics. The novel aspect here is to use state-in-the art techniques to quantify rate limiting steps of individual components involved antibiotic penetration and to validate them at the cellular level. Such a system biology approach identifies bottlenecks of existing antibiotics and might suggest novel antibiotic therapy. In Gram-negative bacteria, where influx and efflux systems located in the Outer Membrane represent a physical bottleneck for any antibiotic to reach a potential target. The aim is to investigate the molecular and cellular mechanisms at the basis of the influx and efflux processes and to teach scientists with different scientific background to go beyond the classical faculty boarder. Bringing nanotechnology, physics, chemistry, computer modeling, pharmacology, microbiology together will facilitate the transfer of expertise acquired within the network in both academic and industry. To achieve these goals we propose a training program allowing young researcher to collaborate across traditional faculty boarder. Three partners from the private sector will actively participate, the first one is a SME developing unique nanodevices allowing high-throughput drug screening in the field of electrophysiology, the second one is engaged in developing novel antibiotics and the third one is working on drug screening and characterization. Moreover three global pharmaceutical companies will accept students for secondments.'